A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study

Clinical Colorectal Cancer - Tập 17 - Trang 147-155 - 2018
Eiji Oki1, Takeshi Kato2, Hideaki Bando3, Takayuki Yoshino3, Kei Muro4, Hiroya Taniguchi4, Yoshinori Kagawa5, Kentaro Yamazaki6, Tatsuro Yamaguchi7, Akihito Tsuji8, Shigeyoshi Iwamoto9, Goro Nakayama10, Yasunori Emi11, Tetsuo Touyama12, Masato Nakamura13, Masahito Kotaka14, Hideki Sakisaka15, Takeharu Yamanaka16, Akiyoshi Kanazawa17
1Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
2Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan
3Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan
4Department of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan
5Department of Colorectal Surgery, Kansai Rosai Hospital, Hyogo, Japan
6Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan
7Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
8Department of Medical Oncology, Kagawa University Hospital, Kagawa, Japan
9Cancer Center, Aichi Medical University, Aichi, Japan
10Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Aichi, Japan
11Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan
12Department of Surgery, Nakagami Hospital, Okinawa, Japan
13Aizawa Comprehensive Cancer Center, Aizawa Hospital, Nagano, Japan
14Gastrointestinal Cancer Center, Sano Hospital, Hyogo, Japan
15Department of Surgery, Kawanishi City Hospital, Hyogo, Japan
16Department of Biostatistics, Yokohama City University School of Medicine, Kanagawa, Japan
17Department of Surgery, Shimane Prefectural Central Hospital, Shimane, Japan

Tài liệu tham khảo

Falcone, 2007, J Clin Oncol, 25, 1670, 10.1200/JCO.2006.09.0928 Loupakis, 2014, Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer, N Engl J Med, 371, 1609, 10.1056/NEJMoa1403108 National Comprehensive Cancer Network Van Cutsem, 2016, ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, Ann Oncol, 27, 1386, 10.1093/annonc/mdw235 Japanese Society for Cancer of the Colon and Rectum, 2016 Yamazaki, 2016, Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G), Ann Oncol, 27, 1539, 10.1093/annonc/mdw206 Japan Society Clinical Oncology Masi, 2010, Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial, Lancet Oncol, 1, 845, 10.1016/S1470-2045(10)70175-3 Kaniwa, 2005, Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American, Drug Metab Dispos, 33, 458, 10.1124/dmd.104.001800 Beutler, 1998, Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?, Proc Natl Acad Sci U S A, 95, 8170, 10.1073/pnas.95.14.8170 Onoue, 2009, UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients, Int J Clin Oncol, 14, 136, 10.1007/s10147-008-0821-z Hoskins, 2007, UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters, J Natl Cancer Inst, 99, 1290, 10.1093/jnci/djm115 Falvella, 2015, DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan, Br J Clin Pharmacol, 80, 581, 10.1111/bcp.12631 Klastersky, 2016, Management of febrile neutropaenia: ESMO Clinical Practice Guidelines, Ann Oncol, 27, v111, 10.1093/annonc/mdw325
Thông tin
Thông tin xuất bản

Clinical Colorectal Cancer

Tập 17

147-155

Thông tin tác giả